2 results
Approved WMOCompleted
Primary1. To demonstrate that 89Zr-CER-001 penetrates into atherosclerotic plaques in patients by means of PET imaging. Secondary 2. To evaluate whether the amount of 89Zr-CER-001 penetrating the plaque corresponds to athero-lesion severity.3. To…
Approved WMOCompleted
Primary Objective:1. To evaluate the efficacy of sonelokimab at 2 different dose levels (120 mg, 240 mg) compared with placebo in the treatment of participants withactive moderate to severe hidradenitis suppurativa.Secondary Objectives:1. To…